Summary
Patients with diabetes due to pancreatectomy have metabolic features different from Type 1 (insulin-dependent) diabetes after insulin withdrawal. Whether or not glucagon by itself or combined glucagon-insulin absence are responsible for this metabolic behaviour is unknown. This study was carried out to evaluate the ability of insulin replacement to abolish differences between patients with Type 1 diabetes and patients with diabetes due to pancreatectomy. We studied the diurnal patterns of intermediary metabolites, free insulin, and glucagon using the Biostator (glucose-controlled insulin infusion system) and intensive subcutaneous insulin therapy in five patients after total pancreatectomy, five after partial pancreatectomy and seven patients with Type 1 diabetes. All were studied for 24 h after an overnight period of normoglycaemia. Insulin requirement was lower in the patients with total pancreatectomy than in patients with partial pancreatectomy or Type 1 diabetes during both types of insulin treatment (p< 0.05). Blood glucose and free insulin were similar in all the groups in both conditions. Immunoreactive glucagon was higher in the patients with diabetes secondary to pancreatectomy than in Type 1 diabetic patients. However, glucagon levels did not increase after arginine infusion in the patients with total pancreatectomy, and column chromatography of blood samples from two totally pancreatectomized patients showed no significant levels of immunoreactive pancreatic glucagon. Non-esterified fatty acids and ketone bodies were similar during Biostator and intensive subcutaneous insulin therapy. By contrast, gluconeogenic precursors (lactate, pyruvate, alanine and glycerol) were higher in patients with total pancreatectomy than in patients with partial pancreatectomy and Type 1 diabetes. In particular, alanine was significantly higher in the patients with total pancreatectomy (400±50 μmol/l during Biostator; 437±62 μmol/l during intensive subcutaneous insulin therapy) than in patients with partial pancreatectomy (207±13 μmol/l, p<0.005 and 226±14 μmol/l, p<0.005) and in Type 1 diabetic patients (191±11 μmol/l, p<0.005 and 216±10 μmol/l, p<0.005). Our data show that the high levels of gluconeogenic precursors, already reported in patients with diabetes due to total pancreatectomy after insulin withdrawal, do not become normal even in the presence of insulin. This finding shows that gluconeogenesis is primarily dependent on pancreatic glucagon and confirms the role of glucagon in the development of diabetic hyperglycaemia.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Unger RH, Orci L (1975) The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1: 14–16
Sakurai H, Dobbs RE, Unger RH (1975) The role of glucagon in the pathogenesis of the endogenous hyperglycaemia of diabetes mellitus. Metabolism 24: 1287–1297
Schade DS, Eaton RP (1975) Modulation of fatty acid metabolism by glucagon in man. Effects in insulin deficient diabetics. Diabetes 24: 510–515
Sherwin RS, Fisher M, Hendler R, Felig P (1976) Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. New Engl J Med 294: 455–461
Aguilar-Parada E, Eisentraut AM, Unger RH (1970) Pancreatic glucagon secretion in normal and diabetic subjects. Am J Med Sci 257: 415–428
Unger RH, Aguilar-Parada E, Muller WA, Eisentraut AM (1970) Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49: 837–848
Muller WA, Faloona GR, Unger RH (1970) Abnormal alpha cell function in diabetes: response to carbohydrate and protein ingestion. N Engl J Med 283: 109–115
Buchanan KD, McCarrol AM (1972) Abnormalities of glucagon metabolism in untreated diabetes mellitus. Lancet 2: 1394–1395
Liljenquist YE, Bomboy YD, Lewis SB, Sinclair-Smith BC, Felts PW, Lacy WW, Crofford OB, Liddle GW (1974) Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men. J Clin Invest 53: 190–197
Gerich JE, Lorenzi M, Bier DM, Schneider V, Tsalikian E, Karam JH, Forsham PH (1975) Prevention of human diabetic ketoacidosis by somatostatin: evidence for an essential role of glucagon. N Engl J Med 292: 985–989
Bank S (1966) The management of diabetes in the unprivileged with special reference to pancreatic diabetes. S Afr Med J 40: 342–345
Bank S, Marks IN, Vinik AI (1975) Clinical and hormonal aspects of pancreatic diabetes. Am J Gastroenterol 64: 13–22
Dettwyler W (1964) Le diabète des pancréatopathies. Sem Hôp Paris 40: 1676–1682
Barnes AJ, Bloom SR, Mashiter K, Alberti KGMM, Smythe P, Turnell D (1977) Persistent metabolic abnormalities in diabetes in the absence of glucagon. Diabetologia 13: 71–75
Barnes AJ, Bloom SR, Alberti KGMM, Smythe P, Alford FP, Chisholm DJ (1977) Ketoacidosis in pancreatectomized man. N Engl J Med 296: 1250–1253
Del Prato S, Nosadini R, Riva F, Fedele D, Devidè A, Tiengo A (1980) Glucagon levels and ketogenesis in human diabetes following total or partial pancreatectomy and severe chronic pancreatitis. Acta Diabetol Lat 17: 111–118
Lloyd B, Burrin J, Smythe P, Alberti KGMM (1978) Enzymic fluorimetric continuous-flow assay for blood glucose, lactate, pyruvate, alanine, glycerol and 3-hydroxybutyrate. Clin Chem 24: 1724–1729
Price CP, Lloyd B, Alberti KGMM (1977) A kinetic spectrophotometric assay for rapid determination of acetoacetate in blood. Clin Chem 23: 1893–1897
Shimuzu S, Inone K, Tani Y, Yamada H (1979) Enzymatic microdetermination of serum free fatty acids. Anal Biochem 98: 341–345
Nagakawa S, Nakayama H, Sajaki T, Yoshino K, Yu YY, Shinozaki K, Aoki S, Mashimo K (1973) A simple method for the determination of serum free insulin levels in insulin-treated patients. Diabetes 22: 590–600
Faloona GR, Unger RH (1974) Glucagon. In: Jaffe BM, Berhman HR (eds) Methods for hormone radioimmunoassay. Academic Press, New York, pp 317–330
Harkins WD, Holladay L (1980) A temperature conversion monogram for glycosylated haemoglobin analysis. Clin Chim Acta 104: 251
Kuzuya T, Matsuda A, Saito T, Yosluda S (1976) Human C-peptide immunoreactivity in blood and urine, evaluation of a radio immunoassay method and its clinical applications. Diabetologia 12: 511–518
Valverde I, Villaneuva ML, Lozano I, Marco J (1974) Presence of glucagon immunoreactivity in the globulin fraction of human plasma (‘big plasma glucagon’). J Clin Endocrinol Metab 39: 1090–1098
Valverde I, Dobbs R, Unger RH (1975) Heterogeneity of plasma glucagon immunoreactivity in normal, depancreatized and alloxan diabetic dogs. Metabolism 24: 1021–1028
Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF (1970) Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 19: 644–655
Newman D (1939) The distribution of range in samples from a normal population, expressed in terms of an independent estimate of standard deviation. Biometrika 31: 20–30
Keuls M (1952) The use of the ‘studentized range’ in connection with an analysis of variance. Euphytica 1: 112–122
Barnes AJ, Bloom SR (1976) Pancreatectomized man: a model for diabetes without glucagon. Lancet 1: 219–221
Tiengo A, Bessioud M, Valverde I, Tabbi-Anneni A, Del Prato S, Alexandre J, Assan R (1982) Absence of islet alpha cell function in pancreatectomized patients. Diabetologia 22: 25–32
Miyata M, Yamamoto T, Yamaguchi M, Nakao K, Yoshida T (1974) Plasma glucagon after total resection of the pancreas in man. Proc Soc Exp Biol (NY) 147: 97–102
Muller WA, Berger M, Suter P, Ceippers HJ, Reiter J, Wyas T, Berchtold P, Schmidt FH, Assal JP, Renold AE (1979) Glucagon immunoreactivities and amino acid profile in plasma of duodeno-pancreatectomized patients. J Clin Invest 63: 820–827
Palmer JP, Werner PL, Benson JW, Ensick JW (1976) Immunoreactive glucagon responses to arginine in three pancreatectomized humans. Metabolism 25 (Suppl 1): 1483–1485
Boden G, Master RW, Rezvani I, Palmer JP, Lobe TE, Owen OE (1980) Glucagon deficiency and hyperaminoacidemia after total pancreatectomy. J Clin Invest 65: 706–716
Damman HG, Besterman HS, Bloom SR, Schreiber H (1981) Guthormone profile in totally pancreatectomized patients. Gut 22: 103–107
Sherwin RS, Fischer M, Bessoff J, Snyder R, Hendler R, Conn HO, Felig P (1978) Hyperglucagonemia in cirrhosis: altered secretion and sensitivity to glucagon. Gastroenterology 74: 1224–1228
Perez G, Trimarco B, Ungaro B, Rengo F, Saccà L (1978) Glucoregularity response to insulin-induced hypoglycaemic in Laennec's cirrhosis. J Clin Endocrinol Metab 46: 778–783
Nosadini R, Del Prato S, Tiengo A, Duner E, Toffolo G, Cobelli C, Faronato PP, Moghetti P, Muggeo M (1982) Insulin sensitivity, binding and kinetics in pancreatogenic and Type I diabetes. Diabetes 31: 346–355
Del Prato S, Ruggeri A, Tessari P, Moghetti P, Manunta R, Duner E, Avogaro A, Fedele D (1981) Reduced insulin sensitivity (IS) in Type I diabetics. Diabetes 30 (Suppl 1): 331 (Abstract)
DeFronzo RA, Handler R, Simonson D (1982) Insulin resistance is a prominent feature of insulin-dependent diabetes. Diabetes 31: 795–801
Cherrington AD (1981) Gluconeogenesis: its regulation by insulin and glucagon. In: Brownlee M. (ed) Diabetes mellitus, Vol. III, Sarland STPM Press, New York, pp 49–117
Wahren J, Hagenfeld L. Felig P (1975) Splanchnic and leg exchange of glucose, amino acids and free fatty acids during exercise in diabetes mellitus. J Clin Invest 55: 1305–1314
Pozefsky T, Tancredi RG, Moxley RT, Dupre J, Tobin JD (1976) Metabolism of forearm tissues in man studies with glucagon. Diabetes 25: 128–135
Ochs RS, Harris RA (1980) Glucagon and N6, O21-dibutyril adenosine 3′–5′ monophosphate. Inhibition of lipigenesis and phosphofructokinase activity of hepatocytes from meal-fed rats. Lipids 15: 504–511
Goriya Y, Bahoric A, Marliss EB, Zinman B, Albisser AM (1981) The metabolic and hormonal responses to a mixed meal in unrestrained pancreatectomized dogs chronically treated by portal or peripheral insulin infusion. Diabetologia 21: 59–64
Felig P, Pozefsky T, Marliss E, Cahill GF Jr. (1969) Alanine key rôle in gluconeogenesis. Science 167: 1003–1004
Rabin D, Müller GL, Lacy WW, Liljenquist JE (1979) Splanchnic metabolism of alanine in intact man: effects of somatostatin and somatostatin plus insulin. Diabetes 28: 486–490
Pozefsky T, Tancredi RG (1972) Effects of intrabrachial arterial infusion of pyruvate on forearm tissue metabolism. Interrelationships between pyruvate, lactate and alanine. J Clin Invest 51: 2359–2369
Cherrington AD, Williams PE, Shulman GI, Lacy WW (1981) Differential time course of glucagon's effect on glycogenolysis and gluconeogenesis in the conscious dog. Diabetes 30: 180–187
Nosadini R, McCulloch A, Del Prato S, Avogaro A, Alberti KGMM (1982) The relationship between alanine and ketone body in vivo. Metabolism 31: 1175–1178
Lefebvre P (1972) Glucagon and lipid metabolism. In: Lefebvre P, Unger RH (eds) Glucagon: molecular physiology, clinical and therapeutic implications. Pergamon Press, New York, pp 109–121
Nosadini R, Noy GA, Nattrass M, Alberti KGMM, Home PD, Johnston DG, Ørskov H (1982) The metabolic response to short-term normoglycaemia in insulin-deficient diabetes: studies with a glucose controlled insulin infusion system (artificial endocrine pancreas). Diabetologia 23: 220–228
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Del Prato, S., Tiengo, A., Baccaglini, U. et al. Effect of insulin replacement on intermediary metabolism in diabetes secondary to pancreatectomy. Diabetologia 25, 252–259 (1983). https://doi.org/10.1007/BF00279939
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00279939